Home Cart Sign in  
Chemical Structure| 13534-90-2 Chemical Structure| 13534-90-2

Structure of 13534-90-2

Chemical Structure| 13534-90-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 13534-90-2 ]

CAS No. :13534-90-2
Formula : C5H3Br2N
M.W : 236.89
SMILES Code : BrC1=C(Br)C=NC=C1
MDL No. :MFCD00234016
InChI Key :ZFZWZGANFCWADD-UHFFFAOYSA-N
Pubchem ID :817106

Safety of [ 13534-90-2 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 13534-90-2 ] Show Less

Physicochemical Properties

Num. heavy atoms 8
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 1.0
Num. H-bond donors 0.0
Molar Refractivity 39.64
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

12.89 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.87
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.23
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.61
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.01
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.8
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.31

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.27
Solubility 0.128 mg/ml ; 0.000539 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.14
Solubility 1.73 mg/ml ; 0.00731 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.74
Solubility 0.0435 mg/ml ; 0.000184 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.16 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.44

Application In Synthesis of [ 13534-90-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 13534-90-2 ]

[ 13534-90-2 ] Synthesis Path-Downstream   1~35

  • 3
  • [ 13534-90-2 ]
  • [ 64-17-5 ]
  • 3,3'-dibromo-[1,4']bipyridyl-4-one [ No CAS ]
  • 6
  • [ 13534-90-2 ]
  • [ 5188-07-8 ]
  • [ 82257-12-3 ]
YieldReaction ConditionsOperation in experiment
86% In N,N-dimethyl-formamide; at 20℃; for 1h;Inert atmosphere; To a solution of <strong>[13534-90-2]3,4-dibromopyridine</strong> (500 mg; 2.11 mmol; 1 eq.) in dry DMF (2 mL) sodium methanethionalate (163 mg; 2.32 mmol; 1.1 eq.) is added portionwise under Ar. After stirring at room temperature for 1 h, the reaction mixture is diluted with EtOAc and the organic layer is washed with water and brine, dried over Na2SO4 and concentrated in vacuo. The residue is purified by FCC (0-50% EtOAc gradient in hexane) to give 3-bromo-4- (methylsulfanyl)pyridine (370 mg; 1.81 mmol; yield: 86%; light yellow oil; UPLC purity: 100%).
  • 7
  • [ 13534-90-2 ]
  • [ 109-72-8 ]
  • [ 96-22-0 ]
  • [ 19731-60-3 ]
  • [ 40247-51-6 ]
  • [ 5582-82-1 ]
  • [ 85452-82-0 ]
  • 8
  • [ 13534-90-2 ]
  • [ 96-22-0 ]
  • [ 19731-60-3 ]
  • [ 40247-51-6 ]
  • [ 5582-82-1 ]
  • [ 85452-82-0 ]
  • 9
  • [ 13534-90-2 ]
  • [ 96-22-0 ]
  • [ 40247-51-6 ]
  • [ 85452-82-0 ]
  • 10
  • [ 13534-90-2 ]
  • [ 96-22-0 ]
  • [ 626-55-1 ]
  • [ 625-92-3 ]
  • [ 1120-87-2 ]
  • [ 107399-34-8 ]
  • 11
  • [ 13534-90-2 ]
  • [ 626-55-1 ]
  • [ 625-92-3 ]
  • [ 1120-87-2 ]
  • 12
  • [ 13534-90-2 ]
  • [ 626-55-1 ]
  • [ 1120-87-2 ]
  • [ 107399-33-7 ]
  • 16
  • [ 13534-90-2 ]
  • [ 100-52-7 ]
  • [ 234111-13-8 ]
  • 4-bromo-α-phenyl-3-pyridinemethanol [ No CAS ]
  • 17
  • [ 13534-90-2 ]
  • 3-bromo-4-methanesulfonylpyridin-1-ium-1-olate [ No CAS ]
  • 19
  • [ 13534-90-2 ]
  • [ 157023-34-2 ]
  • 4-[(3-Bromo-pyridin-4-ylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester [ No CAS ]
YieldReaction ConditionsOperation in experiment
Example 55 4-[(3-Bromo-pyridin-4-ylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester A mixture of benzyl-4-(aminomethyl)piperidine-1-carboxylate (EXAMPLE 13, Step 1, 0.20 g, 0.81 mmol), <strong>[13534-90-2]3,4-dibromo-pyridine</strong> (Chem. Abstracts, 58:5627) (0.19 g, 0.81 mmol) in IPA (0.5 mL) was heated at 100 C. in a sealed reaction tube for 7 h, then concentrated in vacuo. The residue was purified by silica gel chromatography (DCM IPA hexane)) to give 4-[(3-Bromo-pyridin-4-ylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester. M.S.(M+1):405.27.
  • 20
  • [ 13534-90-2 ]
  • [ 36673-36-6 ]
  • [ 171359-41-4 ]
  • [ 171359-40-3 ]
  • 21
  • [ 13534-90-2 ]
  • [ 1692-25-7 ]
  • [ 1356406-39-7 ]
  • 22
  • [ 13534-90-2 ]
  • [ 1198605-53-6 ]
  • 4-(3-bromopyridin-4-yl)-1H-pyrrole-2-carboxylic acid methyl ester [ No CAS ]
YieldReaction ConditionsOperation in experiment
1 g With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; caesium carbonate; In ethanol; water; for 3h;Reflux; Inert atmosphere; A mixture of 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-pyrrole-2-carboxylic acid methyl ester (2.5 g, 10 mmol), <strong>[13534-90-2]3,4-dibromo-pyridine</strong> (2.6 g, 11 mmol), CS2CO3 (6.5 g, 20 mmol) and Pd(dppf)Cl2 (732 mg, 1 mmol) in EtOH (30 mL) and water (5 mL) was refluxed for 3 hours under N2 protection, and then poured into water (100 mL). The aqueous layer was extracted with EtOAc (100 mLx5). The combined organic layers were concentrated. The residue was purified by flash chromatography to give 4-(3-bromo-pyridin-4-yl)-lH-pyrrole-2-carboxylic acid methyl ester (1 g) as a yellow solid.
  • 23
  • [ 13534-90-2 ]
  • 4-(3-bromopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [ No CAS ]
  • 24
  • [ 13534-90-2 ]
  • 4-(3-bromopyridin-4-yl)-1H-pyrrole-2-carboxylic acid amide [ No CAS ]
  • 25
  • bromo(cyclopropyl)zinc [ No CAS ]
  • [ 13534-90-2 ]
  • [ 1357094-98-4 ]
YieldReaction ConditionsOperation in experiment
51% With tetrakis(triphenylphosphine) palladium(0); at 90℃; for 2.5h;Inert atmosphere; Step I: A solution of cyclopropyl zink bromide (0.5 M, 12 mL, 6.0 mmol) was added to ethyl <strong>[13534-90-2]3,4-dibromopyridine</strong> (1.42 g, 6.0 mmol) and Pd(PPh3)4 (347 mg, 0.6 mmol) and the RM was stirred at 90 Cunder an inert atmosphere for 2.5 h. Subsequently, the volatiles were removed under reduced pressure and the residue was dissolved in water and extracted with CH2CI2. The combined organic layers were dried and the volatiles were removed under reduced pressure. The residue was purified by CC (SiC2, EtOAc/Cy (1:2)) to yield the desired compound (600 mg, 51%).LC-MS (Method 1): m/z [M+H] = 198.1 (MW calc. = 196.98); R1 = 2.6 mm. 1H-NMR (CDCI3): oe = 0.79 (m,2H); 1.15 (m, 2H); 2.20 (m, 1H); 6.72 (d, J = 5.2 H, 1H); 8.85 (d, J = 5.2 Hz, IH); 8.63 (s, 1H). 13C-NMR(CDCI3): oe = 9.7; 15.2; 119.9; 123.9; 148.1; 151.3; 152.1.
  • 26
  • [ 13534-90-2 ]
  • C17H20N4O2S [ No CAS ]
  • 27
  • [ 13534-90-2 ]
  • C14H15N3O2 [ No CAS ]
  • 28
  • [ 13534-90-2 ]
  • C21H22N3O2(1+)*Br(1-) [ No CAS ]
  • 29
  • [ 13534-90-2 ]
  • C21H25N3O2 [ No CAS ]
  • 30
  • [ 13534-90-2 ]
  • methyl 5-(1-cyano-4-cyclopropyl-1,2,5,6-tetrahydropyridin-3-yl)-1-methyl-1Hpyrazole-3-carboxylate [ No CAS ]
  • 31
  • [ 13534-90-2 ]
  • 4-methanesulfonyl-3-[8-(1-methyl-1H-indol-6-yl)quinoxalin-6-yl]amino}pyridin-1-ium-1-olate [ No CAS ]
  • 32
  • [ 13534-90-2 ]
  • [ 171364-83-3 ]
  • [ 335642-95-0 ]
YieldReaction ConditionsOperation in experiment
455 mg With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; caesium carbonate; In water; dimethyl sulfoxide; The titled compound was prepared by the reaction of <strong>[13534-90-2]3,4-dibromopyridine</strong> (1.01 g, 4.26 mmol) with 4-nitrophenylboronic acid pinacol ester (1.06 g, 4.26 mmol) using cesium carbonate (2.07 g, 6.39 mmol) and [l, -bis(diphenylphosphino)ferrocene]dichloropalladium (II) (155 mg, 0.21 mmol) in a mixture of DMSO and water (20 mL, 3: 1) as per the procedure described in Step 1 of Intermediate 1 to yield 455 mg of the product; 1H NMR (300 MHz, CDC13) delta 7.33 (d, 7 = 4.8 Hz, 1H), 7.63 (d, 7 = 8.7 Hz, 2H), 8.35 (d, 7 = 8.7 Hz, 2H), 8.64 (d, 7 = 5.1 Hz, 1H), 8.89 (s, 1H) ; ESI-MS (m/z) 281 (M+2H)+.
  • 33
  • [ 13534-90-2 ]
  • [ 171364-83-3 ]
  • 3-(4-chlorophenyl)-4-(4-nitrophenyl)pyridine [ No CAS ]
  • 34
  • [ 13534-90-2 ]
  • [ 1679-18-1 ]
  • 3-bromo-4-(4-chlorophenyl)pyridine [ No CAS ]
YieldReaction ConditionsOperation in experiment
513 mg With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; caesium carbonate; In water; dimethyl sulfoxide; The titled compound was prepared by the reaction of <strong>[13534-90-2]3,4-dibromopyridine</strong> (1.02 g, 4.30 mmol) with 4-chlorophenylboronic acid (673 mg, 4.30 mmol) using cesium carbonate (2.10 g, 6.45 mmol) and [l, -bis(diphenylphosphino)ferrocene]dichloropalladium (II) (157 mg, 0.22 mmol) in a mixture of DMSO and water (20 mL, 3: 1) as per the procedure described in Step 1 of Intermediate 1 to yield 513 mg of the product; 1H NMR (300 MHz, CDC13) delta 7.25 (d, J = 6.9 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 8.54 (d, J = 5.1 Hz, 1H), 8.81 (s, 1H); APCI-MS (m/z) 268 (M)+, 270 (M+2H)+.
  • 35
  • [ 13534-90-2 ]
  • [ 37882-75-0 ]
  • thieno[3,2-b]thiophene-2,5-diylbis((3-bromopyridin-4-yl)methanol) [ No CAS ]
YieldReaction ConditionsOperation in experiment
75% With lithium diisopropyl amide; In tetrahydrofuran; diethyl ether; hexane; at -78 - 24℃; for 12h; Thienothiophene dicarbaldehyde (5 g, 25.48 mmol) is dissolved in 250 mL of dry diethylether and dry tetrahydrofuran (THF) and then, cooled down to -78 C. Then, 42.12 mL of diisopropylamine (a 2.0 M hexane solution) is slowly added thereto in a dropwise fashion, and 2,3-dibromopyridine (13.3 g, 56.16 mmol) is added thereto. The mixture is slowly heated and stirred at room temperature (24 C.) for 12 hours. Subsequently, 100 mL of an ammonium chloride-saturated solution is added thereto, and an extract is obtained by using chloroform and several times washed with water. The obtained extract is dried with magnesium sulfate and then, filtered, and the chloroform solvent is removed to obtain a compound 2a. (a yield of 75%)
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 13534-90-2 ]

Bromides

Chemical Structure| 626-55-1

A825414 [626-55-1]

3-Bromopyridine

Similarity: 0.87

Chemical Structure| 19524-06-2

A156741 [19524-06-2]

4-Bromopyridine hydrochloride

Similarity: 0.83

Chemical Structure| 625-92-3

A222663 [625-92-3]

3,5-Dibromopyridine

Similarity: 0.82

Chemical Structure| 22282-99-1

A177877 [22282-99-1]

4-Bromo-2-methylpyridine

Similarity: 0.77

Chemical Structure| 38749-79-0

A161031 [38749-79-0]

3-Bromo-2-methylpyridine

Similarity: 0.76

Related Parent Nucleus of
[ 13534-90-2 ]

Pyridines

Chemical Structure| 626-55-1

A825414 [626-55-1]

3-Bromopyridine

Similarity: 0.87

Chemical Structure| 19524-06-2

A156741 [19524-06-2]

4-Bromopyridine hydrochloride

Similarity: 0.83

Chemical Structure| 625-92-3

A222663 [625-92-3]

3,5-Dibromopyridine

Similarity: 0.82

Chemical Structure| 22282-99-1

A177877 [22282-99-1]

4-Bromo-2-methylpyridine

Similarity: 0.77

Chemical Structure| 38749-79-0

A161031 [38749-79-0]

3-Bromo-2-methylpyridine

Similarity: 0.76